Scarica l'app Stockscreener
6.92
0.29%
-0.02
Dopo l'orario di chiusura:
6.88
-0.04
-0.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.94
Aprire:
$6.98
Volume 24 ore:
2.64M
Relative Volume:
1.36
Capitalizzazione di mercato:
$1.41B
Reddito:
-
Utile/perdita netta:
$-54.70M
Rapporto P/E:
-20.97
EPS:
-0.33
Flusso di cassa netto:
$-51.36M
1 W Prestazione:
+6.46%
1M Prestazione:
+67.96%
6M Prestazione:
+206.19%
1 anno Prestazione:
+106.57%
Intervallo 1D:
$6.77
$7.005
Intervallo di 1 settimana:
$6.36
$7.005
Portata 52W:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Nome
Savara Inc
Settore
Industria
Telefono
51285113796
Indirizzo
6836 BEE CAVE ROAD, AUSTIN, TX
Confronta SVRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
6.92 | 1.41B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-11-13 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-11-07 | Iniziato | Guggenheim | Buy |
| 2023-05-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-31 | Downgrade | Jefferies | Buy → Hold |
| 2021-03-16 | Iniziato | Piper Sandler | Overweight |
| 2021-03-15 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-13 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Ripresa | ROTH Capital | Neutral |
| 2018-01-03 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-09-27 | Ripresa | ROTH Capital | Buy |
| 2017-09-22 | Iniziato | Jefferies | Buy |
| 2017-09-11 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Savara Inc Borsa (SVRA) Ultime notizie
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI - BioSpace
Savara (SVRA) Is Up 8.9% After European Patent Boost For MOLBREEVI Nebulized Therapy - simplywall.st
Savara (SVRA) Deepens Patent Moat for MOLBREEVI in Europe Is Its Rare-Disease Edge Widening? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Savara Inc. (SVRA) And Encourages Shareholders to Connect - ACCESS Newswire
Savara to Get Patent for Liquid Formulation of Lung Disease Therapy from European Patent Office - marketscreener.com
Savara announces EPO intention to grant Molbreevi patent application - TipRanks
Savara (SVRA) Receives Positive Patent News from European Office - GuruFocus
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* - Yahoo Finance
Savara (NASDAQ:SVRA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Savara stock hits 52-week high at 6.61 USD By Investing.com - Investing.com Canada
Certain Options of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Certain Warrants of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Certain Pre-Funded Warrants of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
172,836,922 Common Stock of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Savara stock hits 52-week high at 6.61 USD - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Savara Inc. (SVRA) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Savara (NASDAQ:SVRA) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Affinity Asset Advisors LLC Purchases New Stake in Savara Inc. $SVRA - MarketBeat
Savara issues patent for Molbreevi from European Patent Office - MSN
Savara rumor highlighted in Betaville blog - MSN
How strong dollar benefits Savara Inc. (YB4P) stock2025 Market WrapUp & Low Drawdown Investment Ideas - Newser
Dir Elam Acquires 4,387 Of Savara Inc [SVRA] - TradingView
Savara Inc. (SVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Savara Inc. (YB4P) stock supported by free cash flowDip Buying & Daily Price Action Insights - Newser
Savara (NASDAQ:SVRA) Shares Up 6.8%What's Next? - MarketBeat
Savara (SVRA) Stock Analysis Report | Financials & Insights - Benzinga
Savara (NASDAQ:SVRA) Reaches New 1-Year HighShould You Buy? - MarketBeat
Will Savara Inc. (YB4P) stock boost dividends furtherWeekly Trade Recap & Breakout Confirmation Alerts - Newser
Is Savara Inc. stock trading near support levelsRecession Risk & AI Optimized Trade Strategies - Newser
Is Savara Inc. (YB4P) stock a top pick for value investorsEarnings Recap Summary & High Return Stock Watch Alerts - Newser
Savara Inc. ticks higher amid takeover speculation - MSN
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System - BioSpace
Savara receives European patent for PAP treatment device By Investing.com - Investing.com Canada
Why analysts upgrade Savara Inc. stockTrade Volume Summary & Weekly High Return Forecasts - Newser
Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences - MSN
Savara to Spotlight Lead Therapy in Fireside Chats at Major Healthcare Conferences - MSN
Savara Inc. (SVRA) Rises Amid Takeover Speculation - GuruFocus
Savara (SVRA) Market Activity Stirred by Acquisition Rumor - GuruFocus
Savara Inc. ticks higher amid takeover speculation (SVRA:NASDAQ) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Savara Inc. (SVRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Savara (NASDAQ:SVRA) Shares Gap DownHere's Why - MarketBeat
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Deliver - PharmiWeb.com
Savara, PARI Granted European Patent Covering Drug-Device Combination - marketscreener.com
Savara (SVRA) Secures European Patent for Drug-Device Combo - GuruFocus
Savara receives European patent for PAP treatment device - Investing.com
Is Savara Inc. (YB4P) stock a top hedge fund pickBull Run & Verified Stock Trade Ideas - Newser
F m Investments LLC Acquires 91,830 Shares of Savara Inc. $SVRA - MarketBeat
10 Small Caps With Big Double-Digit Gains - Insider Monkey
Savara to Resubmit BLA for Rare Lung Disease Treatment as Losses Widen in Q2 - MSN
Savara Stock Surges Amid Positive Financial Developments and Raised Price Target - timothysykes.com
Savara Inc. Sees Price Target Raised Amid Promising Drug Developments - StocksToTrade
Savara Inc Azioni (SVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Savara Inc Azioni (SVRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Nov 14 '25 |
Option Exercise |
1.46 |
5,860 |
8,556 |
121,326 |
| Hawkins Richard J | Director |
Jun 20 '25 |
Buy |
2.04 |
48,225 |
98,572 |
115,466 |
| McCracken Joseph S | Director |
May 29 '25 |
Buy |
2.08 |
10,000 |
20,825 |
260,837 |
| RAMSAY DAVID A | Director |
Mar 31 '25 |
Buy |
2.77 |
150,000 |
416,250 |
2,513,642 |
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):